Last year, ImmuCell Corp generated 27.45M USD for its biggest-performing segment, First Defense® product line. The United States made the largest contribution, accounting for 24.39M USD last year. For the latest quarter, ImmuCell Corp reported the revenue of 7.11M USD for the period ending 2026-06-30, which came from the top-performing segment, First Defense® product line. United States contributed the highest revenue, at 6.23M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

First Defense® product line

Other animal health

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

First Defense® product line

27.45M(99.29%)

26.31M(99.32%)

17.29M(98.98%)

18.41M(99.16%)

18.93M(98.39%)

15.07M(98.24%)

13.24M(96.51%)

Other animal health

196.39K(0.71%)

178.92K(0.68%)

177.74K(1.02%)

156.01K(0.84%)

309.88K(1.61%)

269.76K(1.76%)

344.88K(2.51%)

Other

--(--)

133.60K(0.97%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

24.39M(88.23%)

22.89M(86.41%)

15.95M(91.29%)

17.02M(91.67%)

16.62M(86.37%)

13.64M(88.94%)

12.19M(88.84%)

Other

3.25M(11.77%)

3.60M(13.59%)

1.52M(8.71%)

1.55M(8.33%)

2.62M(13.63%)

1.70M(11.06%)

1.53M(11.16%)